- Especificar que la novel formulation es una fixed-dose coformulation de [[Ivermectina]] y [[Albendazol]].
- Especificar que esta fixed-dose coformulation de ivm/alb has the lowest [[level]] of investment risk of all candidates for Combinations for [[STH]] treatment (fuente: Soil Transmitted Helminths Drug Combinations Expert Meeting, 2016, Gates Foundation)
- El ALIVE trial protocol: https://gatesopenresearch.org/articles/6-62/v1
- Una referencia específica : https://gatesopenresearch.org/articles/6-62/v1